Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital
I'm PortAI, I can summarize articles.
Vivos Therapeutics, Inc. has secured a $2.1 million unsecured loan from Avondale Capital, LLC. The loan, under a Note Purchase Agreement dated December 5, 2025, provides Vivos with approximately $1.5 million in gross proceeds. The note is not convertible into common stock and bears no interest unless in default. Weekly payments start December 12, 2025, with prepayment options available. The loan is guaranteed by Vivos's subsidiary, Airway Integrated Management Company, LLC, and will be used for working capital and general corporate purposes.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments